{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:11Z","timestamp":1759451951891,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.10.062","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T18:40:43Z","timestamp":1667328043000},"page":"7255-7261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice"],"prefix":"10.1016","volume":"40","author":[{"given":"J.C.","family":"Morrill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.E.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-0801","authenticated-orcid":false,"given":"P.M.","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.062_b0005","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00705-017-3358-5","article-title":"Changes to taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses (2017)","volume":"162","author":"Adams","year":"2017","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.20506\/rst.23.2.1500","article-title":"Rift Valley fever","volume":"23","author":"Gerdes","year":"2004","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2022.10.062_b0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0025","doi-asserted-by":"crossref","first-page":"e0004550","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift Valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.062_b0030","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1016\/j.vaccine.2013.09.029","article-title":"Vaccines against diseases transmitted from animals to humans: a one health paradigm","volume":"31","author":"Monath","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0035","first-page":"45","article-title":"An inactivated Rift Valley fever vaccine","volume":"48","author":"Barnard","year":"1977","journal-title":"J S Afr Vet Assoc"},{"key":"10.1016\/j.vaccine.2022.10.062_b0040","doi-asserted-by":"crossref","first-page":"D69","DOI":"10.1016\/j.vaccine.2009.07.046","article-title":"Rift Valley fever vaccines","volume":"27S4","author":"Ikegami","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/vaccines5030029","article-title":"Current status of Rift Valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.10.062_b0050","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","article-title":"One Health approach to Rift Valley fever vaccine development","volume":"106","author":"Kortekaas","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0060","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0065","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2460\/ajvr.1991.52.01.50","article-title":"Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever","volume":"52","author":"Hubbard","year":"1991","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0080","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0085","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir249","article-title":"Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent Rift Valley fever virus","volume":"204","author":"Morrill","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.062_b0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0100","first-page":"394","article-title":"Safety and Immunogenicity of Rift Valley Fever MP-12 and a Novel arMP-12\u0394NSm21\/384 Recombinant Vaccine Candidate in Native Breed of Black Head Sheep (Ovis aries) from Tanzania","volume":"9","author":"Adamson","year":"2018","journal-title":"J Vaccines Vaccin"},{"key":"10.1016\/j.vaccine.2022.10.062_b0105","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/ojvr.v86i1.1683","article-title":"Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12\u0394NSm21\/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania","volume":"86","author":"Nyundo","year":"2019","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley Fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.10.062_b0115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fvets.2020.00238","article-title":"Livestock challenge models of rift valley fever for agricultural vaccine testing","volume":"7","author":"Kroeker","year":"2020","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.vaccine.2022.10.062_b0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.virol.2010.08.016","article-title":"The pathogenesis of Rift Valley fever virus in the mouse model","volume":"407","author":"Smith","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.10.062_b0125","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.4049\/jimmunol.1000949","article-title":"A new mouse model reveals a critical role for host innate immunity in resistance to Rift Valley fever","volume":"185","author":"do Valle","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0130","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1099\/vir.0.042754-0","article-title":"MBT\/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines","volume":"93","author":"Ayari-Fakhfakh","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.virusres.2011.10.023","article-title":"Animal models of Rift Valley fever virus infection","volume":"163","author":"Ross","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0140","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/JVI.06190-11","article-title":"Development of a Novel Nonhuman Primate Model for Rift Valley Fever","volume":"86","author":"Smith","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molimm.2015.02.001","article-title":"Understanding Rift Valley fever: Contributions of animal models to disease characterization and control","volume":"66","author":"Lorenzo","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vetmic.2016.09.009","article-title":"Mouse model for the Rift Valley fever virus MP12 strain infection","volume":"195","author":"Lang","year":"2016","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0155","first-page":"4","article-title":"Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection","author":"McMillen","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2022.10.062_b0160","doi-asserted-by":"crossref","first-page":"e2156","DOI":"10.1371\/journal.pntd.0002156","article-title":"Aerosol Exposure to Rift Valley Fever Virus Causes Earlier and More Severe Neuropathology in the Murine Model, which Has Important Implications for Therapeutic Development","volume":"7","author":"Reed","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.062_b0165","first-page":"11","article-title":"The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses","volume":"49","author":"Coetzer","year":"1982","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0170","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0175","article-title":"AVMA Guidelines for the Euthanasia of Animals","author":"Leary","year":"2013","journal-title":"2013 Edition"},{"key":"10.1016\/j.vaccine.2022.10.062_b0180","doi-asserted-by":"crossref","unstructured":"Guide for the Care and Use of Laboratory Animals National Research Council (US) Institute for Laboratory Animal Research, Washington (DC): National Academies Press (US); 1996. doi:10.17226\/5140.","DOI":"10.17226\/5140"},{"key":"10.1016\/j.vaccine.2022.10.062_b0185","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/v10110651","article-title":"Pathogenesis of Rift Valley Fever Virus Aerosol Infection in STAT2 Knockout Hamsters","volume":"10","author":"Hickerson","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.10.062_b0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0882-4010(87)90126-4","article-title":"Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats","volume":"2","author":"Anderson","year":"1987","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2022.10.062_b0195","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acta Pathol Microbiol Immunol Scand C"},{"key":"10.1016\/j.vaccine.2022.10.062_b0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01311021","article-title":"Experimental Rift Valley fever in rhesus macaques","volume":"99","author":"Peters","year":"1988","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0205","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2022.10.062_b0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jviromet.2005.02.008","article-title":"An inhibition enzyme-linked immunosorbent assay for the detection of antibody to Rift Valley fever virus in humans, domestic and wild ruminants","volume":"127","author":"Paweska","year":"2005","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2022.10.062_b0220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jviromet.2011.07.011","article-title":"Validation of an IgM antibody capture ELISA based on a recombinant nucleoprotein for identification of domestic ruminants infected with Rift Valley fever virus","volume":"177","author":"Williams","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2022.10.062_b0225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2022.10.062_b0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2022.10.062_b0235","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0240","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0245","doi-asserted-by":"crossref","first-page":"e25027","DOI":"10.1371\/journal.pone.0025027","article-title":"Antinucleocapsid protein immune responses counteract pathogenic effectsof Rift Valley fever virus infection in mice","volume":"6","author":"Jansen van Vuren","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2022.10.062_b0250","first-page":"33","article-title":"Induction of virus-inhibiting factor or interferon in mice by strains with different virulence of Rift Valley fever virus","volume":"45","author":"Higashihara","year":"1972","journal-title":"Kitasato Arch Exp Med"},{"key":"10.1016\/j.vaccine.2022.10.062_b0255","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.virol.2011.09.023","article-title":"Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection","volume":"422","author":"McElroy","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.10.062_b0265","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000373924","article-title":"Interplay between the virus and host in Rift Valley fever pathogenesis","volume":"7","author":"Terasaki","year":"2015","journal-title":"J Innate Immun"},{"key":"10.1016\/j.vaccine.2022.10.062_b0270","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/clinids\/11.Supplement_4.S815","article-title":"Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha","volume":"11S4","author":"Morrill","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.062_b0275","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/JVI.07104-11","article-title":"Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge","volume":"86","author":"Dodd","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0280","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/vbz.2009.0205","article-title":"Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates","volume":"10","author":"Busquets","year":"2010","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2022.10.062_b0285","doi-asserted-by":"crossref","first-page":"e1623","DOI":"10.1371\/journal.pntd.0001623","article-title":"Innate Immune Response to Rift Valley Fever Virus in Goats","volume":"6","author":"Nfon","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.062_b0290","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(\u2212\/\u2212) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.062_b0295","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/vaccines8010082","article-title":"MVA vectored vaccines encoding Rift Valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses","volume":"8","author":"Lopez-Gil","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.10.062_b0300","doi-asserted-by":"crossref","first-page":"e01662","DOI":"10.1128\/JVI.01662-17","article-title":"Peripheral blood biomarkers of disease outcome in a monkey model of Rift Valley fever encephalitis","volume":"92","author":"Wonderlich","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0305","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0952-7915(00)00241-7","article-title":"NK cells and NKT cells in innate defense against viral infections","volume":"13","author":"Biron","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2022.10.062_b0310","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/jir.1991.11.297","article-title":"Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey","volume":"11","author":"Morrill","year":"1991","journal-title":"J Interferon Res"},{"key":"10.1016\/j.vaccine.2022.10.062_b0315","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1128\/JVI.00337-13","article-title":"Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses","volume":"87","author":"Dodd","year":"2013","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:20Z","timestamp":1759404080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":63,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22013391"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}